OM:CLS B

Stock Analysis Report

Clinical Laserthermia Systems

Executive Summary

Clinical Laserthermia Systems AB (publ) develops and markets therapies, systems, and single-use instruments for thermal treatment of solid cancer tumors in Sweden.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has Clinical Laserthermia Systems's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLS B's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

31.3%

CLS B

3.9%

SE Medical Equipment

1.1%

SE Market


1 Year Return

-63.2%

CLS B

17.3%

SE Medical Equipment

-9.8%

SE Market

Return vs Industry: CLS B underperformed the Swedish Medical Equipment industry which returned 12.5% over the past year.

Return vs Market: CLS B underperformed the Swedish Market which returned -13.2% over the past year.


Shareholder returns

CLS BIndustryMarket
7 Day31.3%3.9%1.1%
30 Day-9.2%-1.7%-12.7%
90 Day-24.7%-8.9%-20.4%
1 Year-61.8%-63.2%19.2%17.3%-7.5%-9.8%
3 Year-46.8%-49.3%37.9%22.2%3.6%-11.4%
5 Year-36.9%-43.1%30.0%7.2%10.1%-12.8%

Price Volatility Vs. Market

How volatile is Clinical Laserthermia Systems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clinical Laserthermia Systems undervalued compared to its fair value and its price relative to the market?

22.08x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CLS B's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CLS B's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CLS B is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: CLS B is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLS B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLS B is overvalued based on its PB Ratio (22.1x) compared to the SE Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Clinical Laserthermia Systems forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

12.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLS B is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLS B is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLS B is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if CLS B's revenue is forecast to grow faster than the Swedish market.

High Growth Revenue: Insufficient data to determine if CLS B's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CLS B is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Clinical Laserthermia Systems performed over the past 5 years?

-15.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLS B is currently unprofitable.

Growing Profit Margin: CLS B is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CLS B is unprofitable, and losses have increased over the past 5 years at a rate of -15.5% per year.

Accelerating Growth: Unable to compare CLS B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLS B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.6%).


Return on Equity

High ROE: CLS B has a negative Return on Equity (-526.05%), as it is currently unprofitable.


Next Steps

Financial Health

How is Clinical Laserthermia Systems's financial position?


Financial Position Analysis

Short Term Liabilities: CLS B's short term assets (SEK12.5M) do not cover its short term liabilities (SEK30.0M).

Long Term Liabilities: CLS B's short term assets (SEK12.5M) exceed its long term liabilities (SEK608.0K).


Debt to Equity History and Analysis

Debt Level: CLS B's debt to equity ratio (261%) is considered high.

Reducing Debt: CLS B's debt to equity ratio has increased from 0.2% to 261% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLS B has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CLS B has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.6% each year


Next Steps

Dividend

What is Clinical Laserthermia Systems's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLS B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CLS B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLS B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLS B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLS B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

kr1m

CEO Compensation


CEO

Lars-Erik Eriksson

no data

Tenure

kr1,404,000

Compensation

Mr. Lars-Erik T. Eriksson serves as the Chief Executive Officer and Director of Clinical Laserthermia Systems AB (publ). Mr. Eriksson earned MBA in Economics From Lund University in the year 1975 to 1975. 


CEO Compensation Analysis

Compensation vs Market: Lars-Erik's total compensation ($USD0.00) is below average for companies of similar size in the Swedish market ($USD206.46K).

Compensation vs Earnings: Insufficient data to compare Lars-Erik's compensation with company performance.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.


Top Shareholders

Company Information

Clinical Laserthermia Systems AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clinical Laserthermia Systems AB (publ)
  • Ticker: CLS B
  • Exchange: OM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr232.742m
  • Shares outstanding: 45.46m
  • Website: https://www.clinicallaser.se

Location

  • Clinical Laserthermia Systems AB (publ)
  • Medicon Village
  • Scheelevägen 2
  • Lund
  • Skåne County
  • 223 81
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLS BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKApr 2009
LS6DB (Deutsche Boerse AG)YesClass B SharesDEEURApr 2009

Biography

Clinical Laserthermia Systems AB (publ) develops and markets therapies, systems, and single-use instruments for thermal treatment of solid cancer tumors in Sweden. The company offers TRANBERG, a cancer immunotherapy system that includes a laser unit with unique monitoring capabilities and tailored single-use products primarily developed for imILT treatment; and applicator kit. It also is developing products for the treatment of breast, pancreatic, skin, and prostate cancers, as well as other solid cancer tumors. Clinical Laserthermia Systems AB (publ) has a collaboration agreement with Image Guided Therapy SA to develop and commercialize a software product for MR-generated temperature monitoring; and a collaborative license and co-development agreement with MRI Interventions, Inc. to provide navigation and laser ablation platforms for use in spine and neurosurgery. The company is headquartered in Lund, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/06 22:35
End of Day Share Price2020/04/06 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.